<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">47430</article-id><article-id pub-id-type="doi">10.7554/eLife.47430</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-129115"><name><surname>Palit</surname><given-names>Sander AL</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2487-4311</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-139190"><name><surname>Vis</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-139206"><name><surname>Stelloo</surname><given-names>Suzan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-85443"><name><surname>Lieftink</surname><given-names>Cor</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-163671"><name><surname>Prekovic</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-163670"><name><surname>Bekers</surname><given-names>Elise</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-163672"><name><surname>Hofland</surname><given-names>Ingrid</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-139192"><name><surname>Šuštić</surname><given-names>Tonći</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-139193"><name><surname>Wolters</surname><given-names>Liesanne</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20733"><name><surname>Beijersbergen</surname><given-names>Roderick</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-139194"><name><surname>Bergman</surname><given-names>Andries M</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-139195"><name><surname>Győrffy</surname><given-names>Balázs</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-55647"><name><surname>Wessels</surname><given-names>Lodewyk FA</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-31092"><name><surname>Zwart</surname><given-names>Wilbert</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9823-7289</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-139196"><name><surname>van der Heijden</surname><given-names>Michiel S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Division of Molecular Carcinogenesis</institution>, <institution>Netherlands Cancer Institute</institution>, <addr-line><named-content content-type="city">Amsterdam</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff2"><institution content-type="dept">Division of Oncogenomics, Oncode Institute</institution>, <institution>Netherlands Cancer Institute</institution>, <addr-line><named-content content-type="city">Amsterdam</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff3"><institution content-type="dept">Division of Pathology</institution>, <institution>Netherlands Cancer Institute</institution>, <addr-line><named-content content-type="city">Amsterdam</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff4"><institution content-type="dept">Core Facility Molecular Pathology and Biobanking</institution>, <institution>Netherlands Cancer Institute</institution>, <addr-line><named-content content-type="city">Amsterdam</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff5"><institution content-type="dept">Department of Medical Oncology</institution>, <institution>Netherlands Cancer Institute</institution>, <addr-line><named-content content-type="city">Amsterdam</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff6"><institution content-type="dept">TTK Cancer Biomarker Research Group, Institute of Enzymology</institution>, <institution>Semmelweis University</institution>, <addr-line><named-content content-type="city">Budapest</named-content></addr-line>, <country>Hungary</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-3615"><name><surname>Brown</surname><given-names>Myles</given-names></name><role>Reviewing editor</role><aff><institution>Dana-Farber Cancer Institute</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>s.palit@nki.nl</email> (SP);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>ms.vd.heijden@nki.nl</email> (Mv);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>19</day><month>12</month><year>2019</year></pub-date><volume>8</volume><elocation-id>e47430</elocation-id><history><date date-type="received"><day>04</day><month>04</month><year>2019</year></date><date date-type="accepted"><day>19</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Palit et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Palit et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-47430-v1.pdf"/><abstract><p>Androgen receptor (AR) inhibitors represent the mainstay of prostate cancer treatment. In a genome-wide CRISPR-Cas9 screen using LNCaP prostate cancer cells, loss of co-repressor <italic>TLE3</italic> conferred resistance to AR antagonists apalutamide and enzalutamide. Genes differentially expressed upon <italic>TLE3 </italic>loss share AR as the top transcriptional regulator, and <italic>TLE3</italic> loss rescued the expression of a subset of androgen-responsive genes upon enzalutamide treatment. GR expression was strongly upregulated upon AR inhibition in a <italic>TLE3</italic>-negative background. This was consistent with binding of TLE3 and AR at the <italic>GR</italic> locus. Furthermore, GR binding was observed proximal to TLE3/AR-shared genes. GR inhibition resensitized <italic>TLE3</italic><sup>KO</sup> cells to enzalutamide. Analyses of patient samples revealed an association between TLE3 and GR levels that reflected our findings in LNCaP cells, of which the clinical relevance is yet to be determined. Together, our findings reveal a mechanistic link between TLE3 and GR-mediated resistance to AR inhibitors in human prostate cancer.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004622</institution-id><institution>KWF Kankerbestrijding</institution></institution-wrap></funding-source><award-id>NKI2014-7080</award-id><principal-award-recipient><name><surname>van der Heijden</surname><given-names>Michiel S</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004622</institution-id><institution>KWF Kankerbestrijding</institution></institution-wrap></funding-source><award-id>NKI2014-7080</award-id><principal-award-recipient><name><surname>Bergman</surname><given-names>Andries M</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004622</institution-id><institution>KWF Kankerbestrijding</institution></institution-wrap></funding-source><award-id>NKI2014-7080</award-id><principal-award-recipient><name><surname>Zwart</surname><given-names>Wilbert</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Wilbert Zwart, Reviewing editor, <italic>eLife</italic>.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Data for Figure 1 (CRISPR resistance screen) is provided (source data file for Figure 1).Data for Figure 2 (RNA-seq) have been deposited in GEO under accession code GSE130246.Data (ChIP-seq) for Figure 3 and 4 is publicly available (GSE94682).Data for Figure 5C is the TCGA dataset (publicly available).</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Palit S</collab><collab>Vis D</collab><collab>Lieftink C</collab></person-group><year iso-8601-date="2019">2019</year><source>RNA-seq control (sgNT) and TLE3KO (sgTLE3) cells treated with 10 uM enzalutamide or vehicle</source><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE130246">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE130246</ext-link><comment>NCBI Gene Expression Omnibus, GSE130246</comment></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Stelloo S</collab><collab>Nevedomskaya E</collab><collab>Kim Y</collab><collab>Hoekman L et al</collab></person-group><year iso-8601-date="2018">2018</year><source>Endogenous Androgen Receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE94682">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE94682</ext-link><comment>NCBI Gene Expression Omnibus, GSE94682</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-47430-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>